Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 6022

Nektar posts one-year eczema success; Pfizer ends malnutrition trial

$
0
0
Plus, news about Incyte, Evommune, Kainova and Sutro: 📊 Nektar outlines one-year eczema data: The company said its drug rezpegaldesleukin, commonly known as rezpeg, maintained and deepened patients’ skin clearances after a 52-week follow-up period ...

Viewing all articles
Browse latest Browse all 6022

Trending Articles